302 related articles for article (PubMed ID: 18588501)
1. Management of fungal infections following allogeneic stem cell transplantation.
Narimatsu H; Kami M
Expert Rev Anti Infect Ther; 2008 Jun; 6(3):373-84. PubMed ID: 18588501
[TBL] [Abstract][Full Text] [Related]
2. Antifungal prophylaxis following reduced-intensity stem cell transplantation.
Kami M; Murashige N; Tanaka Y; Narimatsu H
Transpl Infect Dis; 2006 Dec; 8(4):190-202. PubMed ID: 17116132
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Girmenia C; Barosi G; Aversa F; Bacigalupo A; Barbui T; Baronciani D; Bosi A; Candoni A; Locasciulli A; Locatelli F; Menichetti F; Musso M; Viscoli C; Rambaldi A
Clin Infect Dis; 2009 Oct; 49(8):1226-36. PubMed ID: 19772390
[TBL] [Abstract][Full Text] [Related]
4. Recent approaches to antifungal therapy for invasive mycoses.
Mathew BP; Nath M
ChemMedChem; 2009 Mar; 4(3):310-23. PubMed ID: 19170067
[TBL] [Abstract][Full Text] [Related]
5. Management of invasive fungal infections: a role for polyenes.
Chandrasekar P
J Antimicrob Chemother; 2011 Mar; 66(3):457-65. PubMed ID: 21172787
[TBL] [Abstract][Full Text] [Related]
6. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
Almyroudis NG; Segal BH
Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1451-66. PubMed ID: 21133669
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
8. [Antifungals for systemic use].
Ruiz-Camps I; Cuenca-Estrella M
Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):353-62. PubMed ID: 19482382
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
[TBL] [Abstract][Full Text] [Related]
10. Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy.
Grigg A; Slavin M
Transpl Infect Dis; 2008 Feb; 10(1):3-12. PubMed ID: 17605732
[TBL] [Abstract][Full Text] [Related]
11. Recent advances and challenges in the treatment of invasive fungal infections.
Shao PL; Huang LM; Hsueh PR
Int J Antimicrob Agents; 2007 Dec; 30(6):487-95. PubMed ID: 17961990
[TBL] [Abstract][Full Text] [Related]
12. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation.
Jansen J; Akard LP; Wack MF; Thompson JM; Dugan MJ; Leslie JK; Mattison R
Mycoses; 2006 Sep; 49(5):397-404. PubMed ID: 16922792
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review.
Sun HY; Singh N
Int J Antimicrob Agents; 2010 Mar; 35(3):211-8. PubMed ID: 20036518
[TBL] [Abstract][Full Text] [Related]
14. Antifungal therapy strategies in hematopoietic stem-cell transplant recipients: early treatment options for improving outcomes.
Chandrasekar P; Ljungman PT
Transplantation; 2008 Jul; 86(2):183-91. PubMed ID: 18645475
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in antifungal prevention and treatment.
Groll AH; Tragiannidis A
Semin Hematol; 2009 Jul; 46(3):212-29. PubMed ID: 19549575
[TBL] [Abstract][Full Text] [Related]
16. New antifungal agents in pediatric practice.
Das S; Shivaprakash MR; Chakrabarti A
Indian Pediatr; 2009 Mar; 46(3):225-31. PubMed ID: 19346570
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single-institution experience.
Zhang P; Jiang EL; Yang DL; Yan ZS; Huang Y; Wei JL; Wang M; Ma QL; Liu QG; Zou DH; He Y; Qiu LG; Feng SZ; Han MZ
Transpl Infect Dis; 2010 Aug; 12(4):316-21. PubMed ID: 20180926
[TBL] [Abstract][Full Text] [Related]
18. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
Metcalf SC; Dockrell DH
J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients?
Salavert M
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S149-53. PubMed ID: 19013340
[TBL] [Abstract][Full Text] [Related]
20. Selecting antifungal agents for the treatment of invasive fungal infections in patients with renal failure.
Moudgal VV; Sobel JD
Curr Opin Investig Drugs; 2004 Aug; 5(8):873-8. PubMed ID: 15600244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
